AR070027A1 - Agentes anti-infecciosos contra el virus hcv - Google Patents
Agentes anti-infecciosos contra el virus hcvInfo
- Publication number
- AR070027A1 AR070027A1 ARP080104045A ARP080104045A AR070027A1 AR 070027 A1 AR070027 A1 AR 070027A1 AR P080104045 A ARP080104045 A AR P080104045A AR P080104045 A ARP080104045 A AR P080104045A AR 070027 A1 AR070027 A1 AR 070027A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- amino
- independently selected
- heterocyclyl
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 2
- 229960005475 antiinfective agent Drugs 0.000 title 1
- 239000004599 antimicrobial Substances 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 28
- 125000000217 alkyl group Chemical group 0.000 abstract 20
- 125000000623 heterocyclic group Chemical group 0.000 abstract 20
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 18
- -1 hydroxy, methyl Chemical group 0.000 abstract 18
- 125000003342 alkenyl group Chemical group 0.000 abstract 17
- 125000000304 alkynyl group Chemical group 0.000 abstract 17
- 125000001475 halogen functional group Chemical group 0.000 abstract 15
- 125000003545 alkoxy group Chemical group 0.000 abstract 14
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 13
- 125000004043 oxo group Chemical group O=* 0.000 abstract 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 11
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 9
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 9
- 150000001875 compounds Chemical class 0.000 abstract 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 5
- 125000005193 alkenylcarbonyloxy group Chemical group 0.000 abstract 4
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 abstract 4
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 4
- 125000005198 alkynylcarbonyloxy group Chemical group 0.000 abstract 4
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 abstract 4
- 125000005884 carbocyclylalkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 abstract 3
- 125000005090 alkenylcarbonyl group Chemical group 0.000 abstract 3
- 125000005137 alkenylsulfonyl group Chemical group 0.000 abstract 3
- 125000005087 alkynylcarbonyl group Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005139 alkynylsulfonyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 abstract 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 125000005280 halo alkyl sulfonyloxy group Chemical group 0.000 abstract 1
- 230000001553 hepatotropic effect Effects 0.000 abstract 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97287707P | 2007-09-17 | 2007-09-17 | |
| US9679108P | 2008-09-13 | 2008-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070027A1 true AR070027A1 (es) | 2010-03-10 |
Family
ID=39948002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104045A AR070027A1 (es) | 2007-09-17 | 2008-09-17 | Agentes anti-infecciosos contra el virus hcv |
| ARP120102873A AR087472A2 (es) | 2007-09-17 | 2012-08-06 | Agentes anti-infecciosos y su uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102873A AR087472A2 (es) | 2007-09-17 | 2012-08-06 | Agentes anti-infecciosos y su uso |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8415351B2 (enExample) |
| EP (2) | EP2725015A1 (enExample) |
| JP (2) | JP5734654B2 (enExample) |
| KR (2) | KR101552474B1 (enExample) |
| CN (2) | CN102746239B (enExample) |
| AR (2) | AR070027A1 (enExample) |
| AU (1) | AU2008302448B2 (enExample) |
| BR (1) | BRPI0816994B8 (enExample) |
| CA (2) | CA2699981C (enExample) |
| CL (2) | CL2008002794A1 (enExample) |
| CO (1) | CO6260076A2 (enExample) |
| CR (2) | CR11316A (enExample) |
| DO (2) | DOP2010000084A (enExample) |
| ES (1) | ES2453591T3 (enExample) |
| GT (1) | GT201000061A (enExample) |
| IL (1) | IL204547A (enExample) |
| IN (1) | IN2012DN05113A (enExample) |
| MX (2) | MX2010002905A (enExample) |
| MY (1) | MY162760A (enExample) |
| NZ (3) | NZ584720A (enExample) |
| PA (1) | PA8796201A1 (enExample) |
| PE (2) | PE20130209A1 (enExample) |
| PH (1) | PH12013500365A1 (enExample) |
| RU (2) | RU2543620C2 (enExample) |
| SG (1) | SG183733A1 (enExample) |
| TW (2) | TWI437994B (enExample) |
| UA (1) | UA117800C2 (enExample) |
| UY (1) | UY31344A1 (enExample) |
| WO (1) | WO2009039127A1 (enExample) |
| ZA (2) | ZA201204223B (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2368879T3 (es) | 2007-09-17 | 2011-11-23 | Abbott Laboratories | Pirimidinas antiinfecciosas y usos de las mismas. |
| US8178548B2 (en) * | 2007-09-17 | 2012-05-15 | Abbott Laboratories | Anti-infective agents and uses thereof |
| EP2725015A1 (en) | 2007-09-17 | 2014-04-30 | AbbVie Bahamas Ltd. | Uracil or thymine derivative for treating hepatitis c |
| US8765757B2 (en) * | 2007-11-16 | 2014-07-01 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| JP2011528686A (ja) | 2008-07-23 | 2011-11-24 | エフ．ホフマン−ラ ロシュ アーゲー | ヘテロ環式抗ウイルス性化合物 |
| KR20110061640A (ko) | 2008-09-26 | 2011-06-09 | 에프. 호프만-라 로슈 아게 | Ｈｃｖ 치료용 피린 또는 피라진 유도체 |
| ES2488821T3 (es) * | 2009-03-24 | 2014-08-29 | Abbvie Bahamas Ltd. | Proceso de preparación de un compuesto antiviral |
| RU2552533C2 (ru) * | 2009-03-25 | 2015-06-10 | Эббви Инк. | Противовирусные соединения и их применения |
| JP2012522013A (ja) * | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ｉｒｅｓ媒介翻訳 |
| CN102448936A (zh) | 2009-04-25 | 2012-05-09 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| TWI428332B (zh) | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | 雜環抗病毒化合物 |
| CN102803212A (zh) * | 2009-06-24 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的杂环化合物 |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| BR112012005616A2 (pt) | 2009-09-21 | 2016-06-21 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| KR20120085918A (ko) * | 2009-11-21 | 2012-08-01 | 에프. 호프만-라 로슈 아게 | 헤테로환형 항바이러스성 화합물 |
| EP2513092A1 (en) * | 2009-12-14 | 2012-10-24 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| EP2590960B1 (en) | 2010-07-07 | 2014-06-11 | F.Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| AU2015201698B2 (en) * | 2010-07-16 | 2017-02-02 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
| EA030228B1 (ru) | 2010-07-16 | 2018-07-31 | ЭббВи Айэленд Анлимитед Компани | Фосфиновые лиганды для каталитических реакций |
| PH12013500105A1 (en) | 2010-07-16 | 2013-02-25 | Abbvie Bahamas Ltd | Process for preparing antiviral compounds |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| EP2603501B1 (en) | 2010-08-13 | 2014-05-14 | F.Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| EP2685964A1 (en) | 2011-03-18 | 2014-01-22 | AbbVie Inc. | Formulations of phenyl uracil compounds |
| JP2014510743A (ja) * | 2011-03-31 | 2014-05-01 | シェファー、コンスタンツェ | 核酸の非ウイルスの導入のためのパーフルオロ化化合物 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5734124B2 (ja) * | 2011-07-21 | 2015-06-10 | 株式会社 東邦アーステック | １，３−ジヨードヒダントイン類の製造方法 |
| AU2012291041A1 (en) | 2011-08-01 | 2014-03-13 | Sumitomo Dainippon Pharma Co., Ltd. | Uracil derivative and use thereof for medical purposes |
| DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
| AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EA026559B1 (ru) | 2012-05-15 | 2017-04-28 | Новартис Аг | Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1 |
| HUE039138T2 (hu) | 2012-05-15 | 2018-12-28 | Novartis Ag | Benzamidszármazékok ABL1, ABL2 és BCR-ABL1 aktivitás gátlására |
| CN104302634B (zh) | 2012-05-15 | 2017-02-08 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 |
| ES2670667T3 (es) | 2012-05-15 | 2018-05-31 | Novartis Ag | Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1 |
| US20140024613A1 (en) | 2012-06-27 | 2014-01-23 | Abbvie Inc. | Methods for Treating HCV |
| JP6469571B2 (ja) | 2012-08-21 | 2019-02-13 | アッヴィ・アイルランド・アンリミテッド・カンパニー | 抗ウイルス性化合物を調製するための方法 |
| CN104853752B (zh) | 2012-10-18 | 2018-10-23 | 艾伯维公司 | 嘧啶二酮衍生物化合物的制剂 |
| JP2014101316A (ja) * | 2012-11-20 | 2014-06-05 | Toyobo Co Ltd | ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法 |
| MX2015017953A (es) | 2013-07-02 | 2016-10-28 | Abbvie Inc | Metodos para tratar el virus de hepatitis c. |
| AR096816A1 (es) | 2013-07-08 | 2016-02-03 | Bayer Cropscience Ag | Derivados de arilsulfuro y arilsulfóxido de seis miembros enlazados con c-n como agentes para combatir parásitos |
| WO2015038596A1 (en) | 2013-09-11 | 2015-03-19 | Emory University | Nucleotide and nucleoside compositions and uses related thereto |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| EP3099295A1 (en) | 2014-01-28 | 2016-12-07 | Abbvie Inc. | Dose adjustment in combination therapy of hepatitis c |
| RS59007B1 (sr) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals Llc | Dihidropirolopiridinski inhibitori ror-gama |
| CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| US20170216252A1 (en) * | 2014-07-11 | 2017-08-03 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| KR102633122B1 (ko) | 2014-08-01 | 2024-02-05 | 누에볼루션 에이/에스 | 브로모도메인에 대하여 활성을 갖는 화합물 |
| WO2016040588A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Treatment of hcv by administering four different anti-hcv compounds with food |
| EA031967B1 (ru) | 2014-10-14 | 2019-03-29 | Вайтаи Фармасьютиклз, Инк. | ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
| WO2016196280A1 (en) | 2015-06-02 | 2016-12-08 | E I Du Pont De Nemours And Company | Heterocycle-substituted bicyclic pesticides |
| WO2017019828A1 (en) * | 2015-07-30 | 2017-02-02 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| KR20180086221A (ko) | 2015-11-20 | 2018-07-30 | 비타이 파마슈티컬즈, 인코포레이티드 | Ror-감마의 조절물질 |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| MA49685A (fr) | 2017-07-24 | 2021-04-14 | Vitae Pharmaceuticals Llc | INHIBITEURS DE ROR gamma |
| CN107266373A (zh) * | 2017-08-01 | 2017-10-20 | 安徽拜善晟制药有限公司 | 一种原料药达沙布韦的制备方法 |
| CN111936498B (zh) | 2018-03-26 | 2024-04-16 | 诺华股份有限公司 | N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物 |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| WO2021053495A1 (en) * | 2019-09-16 | 2021-03-25 | Novartis Ag | Bifunctional degraders and their methods of use |
| EP3819006A1 (en) | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| AU627906B2 (en) * | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| US5084084A (en) * | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| EP0442473B1 (en) | 1990-02-15 | 1998-08-19 | Takeda Chemical Industries, Ltd. | Pyrimidinedione derivatives, their production and use |
| NL9001075A (enExample) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| DK1237878T3 (da) | 1999-12-06 | 2007-07-30 | Hoffmann La Roche | 4-pyrimidinyl-N-acyl-L-phenylanin |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| IL167955A (en) * | 2000-02-04 | 2007-10-31 | Sumitomo Chemical Co | Inilines are converted by troiril |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| TW200505872A (en) * | 2003-06-13 | 2005-02-16 | Lg Life Science Ltd | Hepatitis C virus inhibitors |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| AR061570A1 (es) * | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| ES2368879T3 (es) | 2007-09-17 | 2011-11-23 | Abbott Laboratories | Pirimidinas antiinfecciosas y usos de las mismas. |
| US8178548B2 (en) | 2007-09-17 | 2012-05-15 | Abbott Laboratories | Anti-infective agents and uses thereof |
| EP2725015A1 (en) * | 2007-09-17 | 2014-04-30 | AbbVie Bahamas Ltd. | Uracil or thymine derivative for treating hepatitis c |
| JP2011528686A (ja) | 2008-07-23 | 2011-11-24 | エフ．ホフマン−ラ ロシュ アーゲー | ヘテロ環式抗ウイルス性化合物 |
-
2008
- 2008-09-17 EP EP13193524.9A patent/EP2725015A1/en not_active Withdrawn
- 2008-09-17 EP EP08831873.8A patent/EP2222646B1/en not_active Not-in-force
- 2008-09-17 UY UY31344A patent/UY31344A1/es active IP Right Grant
- 2008-09-17 BR BRPI0816994A patent/BRPI0816994B8/pt active IP Right Grant
- 2008-09-17 NZ NZ584720A patent/NZ584720A/en not_active IP Right Cessation
- 2008-09-17 MX MX2010002905A patent/MX2010002905A/es active IP Right Grant
- 2008-09-17 RU RU2010114828/04A patent/RU2543620C2/ru not_active IP Right Cessation
- 2008-09-17 ES ES08831873.8T patent/ES2453591T3/es active Active
- 2008-09-17 CN CN201210157072.8A patent/CN102746239B/zh not_active Expired - Fee Related
- 2008-09-17 TW TW097135721A patent/TWI437994B/zh active
- 2008-09-17 MY MYPI2010001141A patent/MY162760A/en unknown
- 2008-09-17 NZ NZ600371A patent/NZ600371A/en unknown
- 2008-09-17 TW TW103110394A patent/TWI534137B/zh not_active IP Right Cessation
- 2008-09-17 JP JP2010525102A patent/JP5734654B2/ja not_active Expired - Fee Related
- 2008-09-17 PE PE2012002073A patent/PE20130209A1/es not_active Application Discontinuation
- 2008-09-17 CA CA2699981A patent/CA2699981C/en not_active Expired - Fee Related
- 2008-09-17 CL CL2008002794A patent/CL2008002794A1/es unknown
- 2008-09-17 CN CN200880107764.3A patent/CN101801935B/zh not_active Expired - Fee Related
- 2008-09-17 AU AU2008302448A patent/AU2008302448B2/en active Active
- 2008-09-17 NZ NZ618277A patent/NZ618277A/en not_active IP Right Cessation
- 2008-09-17 PA PA20088796201A patent/PA8796201A1/es unknown
- 2008-09-17 SG SG2012060521A patent/SG183733A1/en unknown
- 2008-09-17 IN IN5113DEN2012 patent/IN2012DN05113A/en unknown
- 2008-09-17 PE PE2008001621A patent/PE20090705A1/es active IP Right Grant
- 2008-09-17 WO PCT/US2008/076576 patent/WO2009039127A1/en not_active Ceased
- 2008-09-17 KR KR1020107008431A patent/KR101552474B1/ko active Active
- 2008-09-17 AR ARP080104045A patent/AR070027A1/es active IP Right Grant
- 2008-09-17 KR KR1020157010052A patent/KR101660360B1/ko not_active Expired - Fee Related
- 2008-09-17 UA UAA201302816A patent/UA117800C2/uk unknown
- 2008-09-17 CA CA2976793A patent/CA2976793A1/en not_active Abandoned
-
2010
- 2010-03-15 GT GT201000061A patent/GT201000061A/es unknown
- 2010-03-16 IL IL204547A patent/IL204547A/en active Protection Beyond IP Right Term
- 2010-03-16 CR CR11316A patent/CR11316A/es unknown
- 2010-03-16 MX MX2012004779A patent/MX338555B/es unknown
- 2010-03-16 DO DO2010000084A patent/DOP2010000084A/es unknown
- 2010-03-16 CO CO10030957A patent/CO6260076A2/es active IP Right Grant
- 2010-03-17 US US12/725,689 patent/US8415351B2/en not_active Expired - Fee Related
- 2010-12-21 DO DO2010000396A patent/DOP2010000396A/es unknown
-
2012
- 2012-04-03 US US13/438,609 patent/US8685991B2/en not_active Expired - Fee Related
- 2012-06-08 ZA ZA2012/04223A patent/ZA201204223B/en unknown
- 2012-06-08 ZA ZA2012/04224A patent/ZA201204224B/en unknown
- 2012-08-06 AR ARP120102873A patent/AR087472A2/es unknown
- 2012-10-11 JP JP2012225875A patent/JP2013049681A/ja active Pending
-
2013
- 2013-02-01 RU RU2013104270/04A patent/RU2599635C2/ru not_active IP Right Cessation
- 2013-02-06 CL CL2013000372A patent/CL2013000372A1/es unknown
- 2013-02-25 PH PH12013500365A patent/PH12013500365A1/en unknown
-
2014
- 2014-03-31 US US14/230,965 patent/US9095590B2/en not_active Expired - Fee Related
-
2015
- 2015-05-08 CR CR20150238A patent/CR20150238A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070027A1 (es) | Agentes anti-infecciosos contra el virus hcv | |
| RU2011142978A (ru) | Противовирусные соединения и их применения | |
| JP2010539186A5 (enExample) | ||
| RU2011142979A (ru) | Противовирусные соединения и их применения | |
| JP2016506960A5 (enExample) | ||
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| HRP20110632T1 (hr) | N-fenil-diokso-hidropirimidini korisni kao inhibitori virusa hepatitisa c (hcv) | |
| AR060609A1 (es) | Compuestos inhibidores de proteinquinasas c-fms. | |
| AR069368A1 (es) | Mezclas fungicidas | |
| JP2019509276A5 (enExample) | ||
| AR068511A1 (es) | Tetrahidro[1,4'] bipiridinil-2'-onas sustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central | |
| EA201500266A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| EA201391158A8 (ru) | Диаминиевые соли фенотиазина и их применение | |
| AR085354A1 (es) | Derivados de isoxazol para control de pestes invertebrados | |
| TN2014000243A1 (fr) | Benzopyrannes nouveaux, compositions les contenant et leurs utilisations | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| JP2014530900A5 (enExample) | ||
| AR056964A1 (es) | Derivados de aminosulfonilo, composiciones farmaceuticas y sus usos | |
| AR065804A1 (es) | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento | |
| AR076412A1 (es) | Compuestos diamida que tienen actividad antagonista de receptores muscarinicos y agonista del receptor adrenergico (beta)2 | |
| EA200801828A3 (ru) | Соединения 1,2,4,5- тетрагидро-3н-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения | |
| AR102939A1 (es) | 3-oxo-3-(arilamino)propanoatos, proceso para prepararlos, y su uso para preparar pirrolidinonas | |
| AR074801A1 (es) | Monocarbamas y composiciones farmaceuticas que los contienen | |
| BRPI0607015A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |